Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchTocilizumabTocilizumab (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

Tocilizumab use in patients with moderate to severe COVID‐19: A retrospective cohort study

Chilimuri et al., Journal of Clinical Pharmacy and Therapeutics, doi:10.1111/jcpt.13303, Oct 2020
https://c19early.org/chilimuri.html
Death/intubation 60% Improvement Relative Risk Tocilizumab  Chilimuri et al.  LATE TREATMENT Is late treatment with tocilizumab beneficial for COVID-19? Retrospective 768 patients in the USA Lower death/intubation with tocilizumab (p=0.0077) c19early.org Chilimuri et al., J. Clinical Pharmacy.., Oct 2020 Favorstocilizumab Favorscontrol 0 0.5 1 1.5 2+
Retrospective 1,225 hospitalized patients showing lower mortality/intubation with tocilizumab.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
risk of death/intubation, 60.0% lower, HR 0.40, p = 0.008, treatment 83, control 685, adjusted per study, propensity score weighting, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chilimuri et al., 24 Oct 2020, retrospective, USA, peer-reviewed, 12 authors.
DOI record: { "DOI": "10.1111/jcpt.13303", "ISSN": [ "0269-4727", "1365-2710" ], "URL": "http://dx.doi.org/10.1111/jcpt.13303", "alternative-id": [ "10.1111/jcpt.13303" ], "assertion": [ { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Received", "name": "received", "order": 0, "value": "2020-08-02" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Accepted", "name": "accepted", "order": 1, "value": "2020-10-06" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Published", "name": "published", "order": 2, "value": "2020-10-24" } ], "author": [ { "affiliation": [ { "name": "Department of Medicine Bronxcare Health SystemAffiliated with Icahn School of Medicine at Mount Sinai Bronx NY USA" } ], "family": "Chilimuri", "given": "Sridhar", "sequence": "first" }, { "ORCID": "https://orcid.org/0000-0002-3625-2870", "affiliation": [ { "name": "Department of Medicine Bronxcare Health SystemAffiliated with Icahn School of Medicine at Mount Sinai Bronx NY USA" } ], "authenticated-orcid": false, "family": "Sun", "given": "Haozhe", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Medicine Bronxcare Health SystemAffiliated with Icahn School of Medicine at Mount Sinai Bronx NY USA" } ], "family": "Alemam", "given": "Ahmed", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Pharmacy Bronxcare Health SystemAffiliated with Icahn School of Medicine at Mount Sinai Bronx NY USA" } ], "family": "Kang", "given": "Kyoung‐Sil", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Pharmacy Bronxcare Health SystemAffiliated with Icahn School of Medicine at Mount Sinai Bronx NY USA" } ], "family": "Lao", "given": "Peter", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Medicine Bronxcare Health SystemAffiliated with Icahn School of Medicine at Mount Sinai Bronx NY USA" } ], "family": "Mantri", "given": "Nikhitha", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Pharmacy Bronxcare Health SystemAffiliated with Icahn School of Medicine at Mount Sinai Bronx NY USA" } ], "family": "Schiller", "given": "Lawrence", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Pharmacy Bronxcare Health SystemAffiliated with Icahn School of Medicine at Mount Sinai Bronx NY USA" } ], "family": "Sharabun", "given": "Myroslava", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Medicine Bronxcare Health SystemAffiliated with Icahn School of Medicine at Mount Sinai Bronx NY USA" } ], "family": "Shehi", "given": "Elona", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Medicine Bronxcare Health SystemAffiliated with Icahn School of Medicine at Mount Sinai Bronx NY USA" } ], "family": "Tejada", "given": "Jairo", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Medicine Bronxcare Health SystemAffiliated with Icahn School of Medicine at Mount Sinai Bronx NY USA" } ], "family": "Yugay", "given": "Alla", "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0002-7829-4024", "affiliation": [ { "name": "Department of Medicine Bronxcare Health SystemAffiliated with Icahn School of Medicine at Mount Sinai Bronx NY USA" } ], "authenticated-orcid": false, "family": "Nayudu", "given": "Suresh Kumar", "sequence": "additional" } ], "container-title": "Journal of Clinical Pharmacy and Therapeutics", "container-title-short": "J Clin Pharm Ther", "content-domain": { "crossmark-restriction": true, "domain": [ "onlinelibrary.wiley.com" ] }, "created": { "date-parts": [ [ 2020, 10, 24 ] ], "date-time": "2020-10-24T08:42:05Z", "timestamp": 1603528925000 }, "deposited": { "date-parts": [ [ 2022, 12, 23 ] ], "date-time": "2022-12-23T18:05:47Z", "timestamp": 1671818747000 }, "indexed": { "date-parts": [ [ 2025, 5, 14 ] ], "date-time": "2025-05-14T01:24:58Z", "timestamp": 1747185898174, "version": "3.40.5" }, "is-referenced-by-count": 9, "issue": "2", "issued": { "date-parts": [ [ 2020, 10, 24 ] ] }, "journal-issue": { "issue": "2", "published-print": { "date-parts": [ [ 2021, 4 ] ] } }, "language": "en", "license": [ { "URL": "http://onlinelibrary.wiley.com/termsAndConditions#vor", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 10, 24 ] ], "date-time": "2020-10-24T00:00:00Z", "timestamp": 1603497600000 } }, { "URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 10, 24 ] ], "date-time": "2020-10-24T00:00:00Z", "timestamp": 1603497600000 } } ], "link": [ { "URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13303", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://onlinelibrary.wiley.com/doi/full-xml/10.1111/jcpt.13303", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13303", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "311", "original-title": [], "page": "440-446", "prefix": "10.1155", "published": { "date-parts": [ [ 2020, 10, 24 ] ] }, "published-online": { "date-parts": [ [ 2020, 10, 24 ] ] }, "published-print": { "date-parts": [ [ 2021, 4 ] ] }, "publisher": "Wiley", "reference": [ { "DOI": "10.24171/j.phrp.2020.11.2.03", "doi-asserted-by": "publisher", "key": "e_1_2_8_2_1" }, { "DOI": "10.1007/s00134-020-06083-6", "article-title": "Stages or phenotypes? A critical look at COVID‐19 pathophysiology", "author": "Jain A", "doi-asserted-by": "crossref", "first-page": "1494", "issue": "7", "journal-title": "Intensive Care Med", "key": "e_1_2_8_3_1", "volume": "46", "year": "2020" }, { "DOI": "10.1007/s00134-020-06088-1", "doi-asserted-by": "publisher", "key": "e_1_2_8_4_1" }, { "DOI": "10.1016/S0140-6736(20)30628-0", "doi-asserted-by": "publisher", "key": "e_1_2_8_5_1" }, { "DOI": "10.1172/JCI137647", "doi-asserted-by": "publisher", "key": "e_1_2_8_6_1" }, { "DOI": "10.1016/S0140-6736(20)30211-7", "doi-asserted-by": "publisher", "key": "e_1_2_8_7_1" }, { "DOI": "10.1001/jamainternmed.2020.0994", "doi-asserted-by": "publisher", "key": "e_1_2_8_8_1" }, { "DOI": "10.1002/jmv.25900", "doi-asserted-by": "publisher", "key": "e_1_2_8_9_1" }, { "DOI": "10.1016/j.cytox.2020.100029", "doi-asserted-by": "publisher", "key": "e_1_2_8_10_1" }, { "DOI": "10.3949/ccjm.87a.ccc018", "article-title": "Practical aspects of targeting IL‐6 in COVID‐19 disease", "author": "Calabrese C", "doi-asserted-by": "crossref", "journal-title": "Cleve Clin J Med", "key": "e_1_2_8_11_1", "year": "2020" }, { "key": "e_1_2_8_12_1", "unstructured": "FDA.FDA approves tisagenlecleucel for B‐cell ALL and tocilizumab for cytokine release syndrome.https://www.fda.gov/drugs/resources‐information‐approved‐drugs/fda‐approves‐tisagenlecleucel‐b‐cell‐all‐and‐tocilizumab‐cytokine‐release‐syndrome. Accessed May 30 2020." }, { "DOI": "10.1016/j.jcv.2020.104443", "doi-asserted-by": "publisher", "key": "e_1_2_8_13_1" }, { "key": "e_1_2_8_14_1", "unstructured": "Clinicaltrials.gov.CORIMUNO‐19 ‐ Tocilizumab Trial ‐ TOCI (CORIMUNO‐TOCI) (CORIMUNO‐TOC).https://Clinicaltrials.gov.ct2/show/NCT04331808. Accessed August 1 2020." }, { "key": "e_1_2_8_15_1", "unstructured": "Greater Paris University Hospitals A‐H.Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID‐19 pneumonia.https://www.aphp.fr/contenu/tocilizumab‐improves‐significantly‐clinical‐outcomes‐patients‐moderate‐or‐severe‐covid‐19. Published 2020. Accessed October 15 2020." }, { "DOI": "10.1073/pnas.2005615117", "doi-asserted-by": "publisher", "key": "e_1_2_8_16_1" }, { "key": "e_1_2_8_17_1", "unstructured": "SAS software. Copyright © [2020] SAS Institute Inc.SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. Cary NC USA." }, { "DOI": "10.1080/00273171.2011.568786", "doi-asserted-by": "publisher", "key": "e_1_2_8_18_1" }, { "key": "e_1_2_8_19_1", "unstructured": "Clinicaltrials.gov.https://clinicaltrials.gov/ct2/results?cond=Covid‐19&term=tocilizumab&cntry=&state=&city=&dist. Accessed May 30 2020." }, { "key": "e_1_2_8_20_1", "unstructured": "Clinicaltrials.gov.https://Clinicaltrials.gov.ct2/results?cond=COVID&term=sarilumab&cntry=&state=&city=&dist. Accessed May 30 2020." }, { "key": "e_1_2_8_21_1", "unstructured": "TarrytownNY ParisX.Regeneron and sanofi provide update on U.S. phase 2/3 adaptive‐designed trial of Kevzara® (Sarilumab) in hospitalized COVID‐19 patients. 2020.www.fda.gov/medwatch. Accessed May 15 2020." }, { "DOI": "10.1111/jdv.16620", "doi-asserted-by": "publisher", "key": "e_1_2_8_22_1" }, { "DOI": "10.1093/rheumatology/keq343", "doi-asserted-by": "publisher", "key": "e_1_2_8_23_1" }, { "key": "e_1_2_8_24_1", "unstructured": "COVID‐19 Treatment Guidelines Panel.Coronavirus disease 2019 (COVID‐19) treatment guidelines. National institutes of health. http://COVID-19TreatmentGuidelinesPanelhttps://www.covid19treatmentguidelines.nih.gov/. Accessed May 30 2020." } ], "reference-count": 23, "references-count": 23, "relation": {}, "resource": { "primary": { "URL": "https://onlinelibrary.wiley.com/doi/10.1111/jcpt.13303" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Tocilizumab use in patients with moderate to severe COVID‐19: A retrospective cohort study", "type": "journal-article", "update-policy": "https://doi.org/10.1002/crossmark_policy", "volume": "46" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit